Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking CessationA Randomized Controlled Trial

Top Cited Papers
Open Access
Publisher Website
Google Scholar
Abstract
Cigarette smoking remains the leading preventable cause of illness and premature death in the United States, claiming an estimated 438 000 lives per year.1 Research over the past 3 decades has identified effective treatments for smoking, including counseling, social support, and several pharmacotherapies.2 However, current pharmacological and nonpharmacological smoking cessation treatments have limited efficacy and are not widely disseminated to the general population of smokers.3,4 Improvements are needed, both in the efficacy of current treatment and in the dissemination of current therapies.